Caladrius Biosciences (NASDAQ: CLBS) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Caladrius Biosciences to similar companies based on the strength of its earnings, analyst recommendations, profitability, dividends, valuation, institutional ownership and risk.
This is a breakdown of recent ratings and recommmendations for Caladrius Biosciences and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Caladrius Biosciences Competitors||547||2488||6705||128||2.65|
Risk and Volatility
Caladrius Biosciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Caladrius Biosciences’ competitors have a beta of 1.52, suggesting that their average share price is 52% more volatile than the S&P 500.
This table compares Caladrius Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Caladrius Biosciences Competitors||-4,491.82%||-467.83%||-42.40%|
Earnings & Valuation
This table compares Caladrius Biosciences and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Caladrius Biosciences||$35.28 million||-$32.65 million||1.59|
|Caladrius Biosciences Competitors||$217.36 million||-$39.57 million||-64.36|
Caladrius Biosciences’ competitors have higher revenue, but lower earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
6.4% of Caladrius Biosciences shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 13.1% of Caladrius Biosciences shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Caladrius Biosciences beats its competitors on 8 of the 13 factors compared.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
What are top analysts saying about Caladrius Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Caladrius Biosciences and related companies.